Delving into the Latest Updates on Munich Biotech AG with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

TOP1(DNA拓扑异构酶I)	1

关联

2

项与 Munich Biotech AG 相关的药物

EndoTAG 2

靶点

TOP1

作用机制

TOP1抑制剂

在研机构

Munich Biotech AG [+1]

原研机构

The University of California, San Francisco

在研适应症

肿瘤

非在研适应症

实体瘤

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

LipoRed

靶点-

作用机制

诊断染料分子

在研机构-

原研机构

MediGene AG

在研适应症-

非在研适应症

肿瘤 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Munich Biotech AG 相关的临床结果

登录后查看更多信息

0 项与 Munich Biotech AG 相关的专利（医药）

登录后查看更多信息

4

项与 Munich Biotech AG 相关的文献（医药）

2004-01-01·Deutsche Gesellschaft für Chirurgie

Dynamische Magnetresonanztomographie zum Monitoring der Effektivität einer antivaskulären Tumortherapie durch Paclitaxel enkapsuliert in kationische Lipidkomplexe

作者: M. Dellian ; H Ruhstorfer ; S. Strieth ; J. Griebel ; M.E. Eichhorn ; A. Werner ; U. Michaelis ; G. Brix ; K.-W. Jauch ; S. Becker

Background: Systemically administrated cationic lipid complexes accumulate selectively in angiogenic tumor endothelium. The chemotherapeutic agent paclitaxel was encapsulated into these lipid complexes, providing an anti-neovascular targeting agent (MBT-0206). In the current study the effect of MBT-0206 on the tumor vasculature was investigated by dynamic magnetic resonance tomography (dMRT). Material and methods: On day 5, 6 and 7 after subcutaneous inoculation of A-MEL-3 tumor cells into Syrian golden hamsters, the animals were treated by i.v. injection of MBT-0206 followed by dMRT measurements at day 8. Untreated tumors were analyzed as a control. The intratumoral blood volume (BV) and the permeability-surface area product within the tumor were calculated from MRI data using a tracer kinetic model. Results: The treatment with MBT-0206 resulted in a significant inhibition of tumor growth compared to the control group. The intratumoral BV of MBT-0206 treated animals was significantly reduced by 34% compared to untreated controls. In addition, the permeability-surface area product in the MBT-0206 treated tumors was increased. Immunohistochemical analysis revealed a significant reduction of the microvascular density in the MBT-0206 treated tumors by 60%. Conclusion: The anti-vascular tumor therapy with MBT-0206 resulted in a functional impairment of the tumor vasculature. dMRT represents an useful approach to quantify the anti-vascular treatment effects, thus providing an attractive surrogate measure of the therapeutic effectiveness of MBT-0206 in clinical trials.

2004-01-01·Deutsche Gesellschaft für Chirurgie

Steigerung des anti-tumorigenen Effekts durch Kombination von MBT-0206 mit Standard-Chemotherapie in einem hoch metastatischen humanen Pankreaskarzinom-Mausmodell

作者: A. Papyan ; K.-W. Jauch ; C. J. Bruns ; U. Michaelis ; M. Teifel ; A. Werner ; I. Ischenko

In the current study we investigated the anti-cancer potential of a combination therapy of MBT-0206 with the standard chemotherapy gemcitabine against highly metastatic human pancreatic cancer (L3.6pl) growing orthotopically in nude mice.

Cationic liposomes (catioms) to target tumor neovasculature

作者: Mundus, Carsten ; Schulze, Brita ; Naujoks, Kurt ; Michaelis, Uwe

The potential of neutral liposomes for drug delivery is well known.Recently, cationic liposomes (Catioms-) have been shown to target and bind to angiogenic endothelial cells lining the tumor blood vessels in animals and humans.Here we present data allowing the pharmaceutical application of Catioms- for imaging or therapy of tumors in humans.Various cytostatic compounds such as paclitaxel or camptothecin have been encapsulated in Catioms- and stable colloidal formulations have been preparedThe therapeutic potential and tolerability of the resp. cytostatics in Catioms- was in animal studies superior to that of the free (nonliposomal) drug.Process development from lab scale to pilot plant production, according to cGMP, was carried out successfully.After lyophilization, excellent storage stabilities and in-use stabilities have been achieved.Several clin. studies with LipoPac- (cationic liposomal formulation of paclitaxel) and LipoRed- (Catioms- with fluorescent label) are ongoing.

100 项与 Munich Biotech AG 相关的药物交易

登录后查看更多信息

100 项与 Munich Biotech AG 相关的转化医学

登录后查看更多信息